Literature DB >> 31016557

Pitfalls of using numerical predictive checks for population physiologically-based pharmacokinetic model evaluation.

Anil R Maharaj1, Huali Wu1, Christoph P Hornik1,2, Michael Cohen-Wolkowiez3,4.   

Abstract

Comparisons between observed data and model simulations represent a critical component for establishing confidence in population physiologically-based pharmacokinetic (Pop-PBPK) models. Numerical predictive checks (NPC) that assess the proportion of observed data that correspond to Pop-PBPK model prediction intervals (PIs) are frequently used to qualify such models. We evaluated the effects of three components on the performance of NPC for qualifying Pop-PBPK model concentration-time predictions: (1) correlations (multiple samples per subject), (2) residual error, and (3) discrepancies in the distribution of demographics between observed and virtual subjects. Using a simulation-based study design, we artificially created observed pharmacokinetic (PK) datasets and compared them to model simulations generated under the same Pop-PBPK model. Observed datasets containing uncorrelated and correlated observations (± residual error) were formulated using different random-sampling techniques. In addition, we created observed datasets where the distribution of subject body weights differed from that of the virtual population used to generate model simulations. NPC for each observed dataset were computed based on the Pop-PBPK model's 90% PI. NPC were associated with inflated type-I-error rates (> 0.10) for observed datasets that contained correlated observations, residual error, or both. Additionally, the performance of NPC were sensitive to the demographic distribution of observed subjects. Acceptable use of NPC was only demonstrated for the idealistic case where observed data were uncorrelated, free of residual error, and the demographic distribution of virtual subjects matched that of observed subjects. Considering the restricted applicability of NPC for Pop-PBPK model evaluation, their use in this context should be interpreted with caution.

Entities:  

Keywords:  Model evaluation; Numerical predictive check; Physiologically-based pharmacokinetic; Prediction interval; Simulation-based study

Mesh:

Year:  2019        PMID: 31016557      PMCID: PMC6531337          DOI: 10.1007/s10928-019-09636-5

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.410


  16 in total

Review 1.  Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.

Authors:  Stephen B Duffull; Daniel F B Wright; Helen R Winter
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

2.  Evaluation of different tests based on observations for external model evaluation of population analyses.

Authors:  Karl Brendel; Emmanuelle Comets; Céline Laffont; France Mentré
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-12-23       Impact factor: 2.745

3.  Tissue distribution of basic drugs: accounting for enantiomeric, compound and regional differences amongst beta-blocking drugs in rat.

Authors:  Trudy Rodgers; David Leahy; Malcolm Rowland
Journal:  J Pharm Sci       Date:  2005-06       Impact factor: 3.534

4.  Physiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions.

Authors:  Weize Huang; Mariko Nakano; Jennifer Sager; Isabelle Ragueneau-Majlessi; Nina Isoherranen
Journal:  Drug Metab Dispos       Date:  2017-08-31       Impact factor: 3.922

5.  A Physiologically Based Pharmacokinetic Model to Describe Artemether Pharmacokinetics in Adult and Pediatric Patients.

Authors:  Wen Lin; Tycho Heimbach; Jay Prakash Jain; Rakesh Awasthi; Kamal Hamed; Gangadhar Sunkara; Handan He
Journal:  J Pharm Sci       Date:  2016-08-06       Impact factor: 3.534

6.  Basic concepts in population modeling, simulation, and model-based drug development-part 2: introduction to pharmacokinetic modeling methods.

Authors:  D R Mould; R N Upton
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-04-17

7.  Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs.

Authors:  Stefan Willmann; Karsten Höhn; Andrea Edginton; Michael Sevestre; Juri Solodenko; Wolfgang Weiss; Jörg Lippert; Walter Schmitt
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-03-13       Impact factor: 2.410

8.  Physiologically based pharmacokinetic modeling and simulation in pediatric drug development.

Authors:  A R Maharaj; A N Edginton
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2014-10-22

9.  Development of an Adult Physiologically Based Pharmacokinetic Model of Solithromycin in Plasma and Epithelial Lining Fluid.

Authors:  Sara N Salerno; Andrea Edginton; Michael Cohen-Wolkowiez; Christoph P Hornik; Kevin M Watt; Brian D Jamieson; Daniel Gonzalez
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-10-25

10.  Application of physiologically based pharmacokinetic modeling to predict acetaminophen metabolism and pharmacokinetics in children.

Authors:  X-L Jiang; P Zhao; J S Barrett; L J Lesko; S Schmidt
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2013-10-16
View more
  1 in total

1.  Use of normalized prediction distribution errors for assessing population physiologically-based pharmacokinetic model adequacy.

Authors:  Anil R Maharaj; Huali Wu; Christoph P Hornik; Antonio Arrieta; Laura James; Varsha Bhatt-Mehta; John Bradley; William J Muller; Amira Al-Uzri; Kevin J Downes; Michael Cohen-Wolkowiez
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-04-22       Impact factor: 2.410

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.